BCRX vs MRK
BioCryst Pharmaceuticals, Inc. vs Merck & Co. — AI-powered side-by-side comparison
BCRX
BioCryst Pharmaceuticals, Inc.
55
Watch
VS
| Metric | BCRX | MRK |
|---|
| AI Score |
55
|
70
|
| Price |
$10.35
|
$130.34
|
| P/E Ratio |
-7.19×
|
103.53×
|
| ROE |
-221.4%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
23.5%
|
75.4%
|
| Debt / Equity |
-0.90×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
75.0
|
64.5
|
| Beta |
0.554
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BCRX versus MRK.
MRK leads by 15 points.
MRK scores 70/100 (Buy) versus BCRX at 55/100 (Watch).
BCRX Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 68.7% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 2.09) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 68.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 13.9x prices in significant intangible value — Value
- ROE of only -328.8% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.09 adds balance-sheet risk to the value case — Value
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical